Herantis Pharma Oyj

Helsinki Stock Exchange HRTIS.HE

Herantis Pharma Oyj Free Cash Flow Yield on January 14, 2025: -15.11%

Herantis Pharma Oyj Free Cash Flow Yield is -15.11% on January 14, 2025, a 0.29% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Herantis Pharma Oyj 52-week high Free Cash Flow Yield is -12.58% on May 31, 2024, which is 16.74% above the current Free Cash Flow Yield.
Herantis Pharma Oyj 52-week low Free Cash Flow Yield is -20.07% on November 15, 2024, which is -32.84% below the current Free Cash Flow Yield.
Herantis Pharma Oyj average Free Cash Flow Yield for the last 52 weeks is -16.01%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

Helsinki Stock Exchange: HRTIS.HE

Herantis Pharma Oyj

CEO	Dr. Antti Vuolanto D.Sc. (Tech)
IPO Date	June 11, 2014
Location	Finland
Headquarters	Bertel Jungin Aukio 1
Employees	11
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying CDNF-based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic version of the active parent as the preclinical xCDNF candidate for the treatment of PD and other neurodegenerative diseases; and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein that is in Phase I study in patients with PD. The company was incorporated in 2008 and is based in Espoo, Finland.

Key trends

Past 5 years